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ABSTRACT
Successful allergen-specific immunotherapy (AIT) is associated with a marked decrease in symptoms on aller-
gen exposure, a reduced requirement for ‘rescue’ anti-allergic drugs and improvement in patients’ quality of life.
These benefits persist for at least several years following discontinuation of immunotherapy - the hallmark of
clinical and immunological tolerance. AIT has been shown to modulate both innate and adaptive immunological
responses. Early suppression of innate effector cells of allergic inflammation (mast cells, basophils), regulation
of pro-allergic T helper 2 type (Th 2) responses and IgE+ B cell responses have been shown to occur both in
the tissue and in the peripheral blood during AIT. The allergen-tolerant state is associated with local and sys-
temic induction of distinct populations of allergen-specific T regulatory cells including IL-10+ Tregs (Tr1 cells),
TGF-β+ Tregs and FoxP3+ memory T regs. B cells are switched in favour of producing IgG (particularly IgG4)
antibodies and associated blocking activity for IgE-dependent events, including basophil activation and IgE-
facilitated allergen binding to B cells. An induction of IL-10+ B regulatory cells and alterations in dendritic cell
subsets have also recently been described. These events are followed by the induction of T regulatory cells,
suppression of allergen-specific T cell proliferation and immune deviation from Th2 in favour of Th1 responses.
Alternative mechanisms of tolerance include apoptosisdeletion of antigen-specific memory Th2 cells andor a
failure of co-stimulation leading to T cell anergy.
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INTRODUCTION
Allergic rhinitis (AR) is an IgE-mediated chronic in-
flammatory disease of the lining of the nasal mucosa.1
AR is the most common allergic disease in Japan,
Western Europe and the United States of America. Its
prevalence has increased in recent decades and is
still on the rise worldwide.1-4 It represents a major
socio-economic and health burden.5 Pharmacother-
apy such as anti-histamines and nasal corticosteroids
are effective in the majority of patients. Conversely, in
a small proportion of patients, symptoms are not ade-
quately controlled despite high doses of medications.
In these patients, allergen immunotherapy (AIT) may
be indicated. AIT is currently the only disease modi-
fying treatment for IgE-mediated allergies that is as-
sociated with long-term clinical and immunological
tolerance. AIT was initially reported in the early 20th
century by Leonard Noon. He described his initial ob-
servations on effects of pollen-specific injection immu-
notherapy resulting in suppression of allergen-
induced ocular symptoms.6 AIT is conventionally ad-
ministered by the subcutaneous route (Subcutaneous
immunotherapy: SCIT).1 It has proven efficacy in
adults and children who have allergy to house dust
mite, animal danders and pollen-induced allergic
rhinitis withwithout asthma.1 In recent years, sublin-
gual immunotherapy (SLIT) has been shown to be ef-
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fective and has a superior safety profile compared to
SCIT. The efficacy of both SCIT and SLIT for sea-
sonal and perennial allergic rhinitis has been con-
firmed in recent systematic meta-analyses.7-10 In this
article, we briefly review evidence for efficacy and
present an overview of the immunological mecha-
nisms associated with tolerance induction during and
after discontinuation of AIT.
CLINICAL BENEFITS OF AIT
AIT is effective and is current standard practice, espe-
cially in those allergic patients who do not respond to
pharmacotherapy.11-13 The efficacy of AIT has been
validated using several allergens including grass and
tree pollen,14,15 house dust mite,16 insect venom17 and
animal dander.18 AIT administered either as SCIT or
SLIT confers long-term clinical benefit for at least sev-
eral years after discontinuation of treatment.11,19-21 In
pollen-induced hayfever, SCIT showed greater clini-
cal effect size in reducing nasal and ocular symptom
scores when compared to antihistamines.22 A com-
prehensive systematic review of the clinical efficacy
of SCIT in patients with seasonal allergic rhinitis in
collaboration with the Cochrane database evaluated
fifty one randomised controlled trials with 2871 par-
ticipants.8 A significant reduction of standardized
mean difference in symptoms versus placebo was ob-
served (SMD: -0.73, 95% Confidence Intervals (CI):
0.97 to -0.50, p < 0.00001). Assessment of requirement
of rescue medication scores in 13 studies revealed a
significant reduction in usage of medication intake
(SMD: -0.57, 95% CI: -0.82 to -0.33, p < 0.00001) in ac-
tively treated subjects. SCIT reduced the onset of
new sensitisations in children23 and there is evidence
that SCIT may prevent the progression of allergic
rhinitis to asthma.21 Specific immunotherapy has
long-term preventive effects on seasonal and peren-
nial asthma as shown in the 10-year preventive al-
lergy treatment study (PAT study).21 Clinical respon-
siveness to SCIT has been shown to exceed the dura-
tion of treatment by several years, a clear advantage
over the use of anti-IgE or anti-allergic drugs.11,24 A
recent updated Cochrane systemic review and meta-
analysis focussed on the use of sublingual immuno-
therapy (SLIT) in allergic rhinitis, including both sea-
sonal and perennial disease and in adult and paediat-
ric populations. There was a significant reduction in
total symptom scores (SMD; -0.49, 95% CI -0.64 to
-0.34, P < 0.001) and rescue medication (SMD; -0.32,
95% CI -0.43, -0.21, p < 0.001) compared to placebo-
treated participants.25 To date, two randomised pla-
cebo controlled trials of SLIT for Japanese cedar polli-
nosis have been reported.26,27 SLIT-treated patients
exhibited significantly lower symptom scores com-
pared to placebo and furthermore SLIT for Japanese
cedar pollinosis significantly improved rhinitis quality
of life scores.
IMMUNOLOGIC MECHANISMS AND TOL-
ERANCE INDUCTION BY AIT
AIT provides a useful human model for studying the
induction of clinical and immunological tolerance. Im-
munologic tolerance induced by allergen immuno-
therapy involves several phases. The allergen-
induced early and late-phase response in the skin and
nose may be used as a clinical surrogate to monitor
tolerance. An early event is the suppression of the
allergen-induced late cutaneous responses within 2-4
weeks of commencing immunotherapy and at low
doses of allergen immunotherapy before onset of
clinical efficacy. In contrast, the IgE-mediated imme-
diate response in the skin is only partially suppressed
by immunotherapy and with a more prolonged time
course that becomes evident at 8-16 weeks that corre-
sponds temporally with an increase in IgG antibodies
and increases in serum IgG-associated inhibitory ac-
tivity for both IgE-dependent basophil activation and
IgE-facilitated binding of allergen-IgE complexes to B
cells28 (Fig. 1). There is also an early desensitisation
of basophil effector cell function as reflected by a de-
crease in allergen-stimulated surface expression of
CD63.29
There is an early induction of IL-10 and TGF-β pro-
ducing T regulatory (Treg) T cells, likely preceded
by activation of so-called ‘protolerogenic’ dendritic
cells.30 There follows down regulation of allergen-
specific T cell responses and a delayed shift in the T
helper type 2 phenotype in favour of Th1 responses.
Changes in serum antibodies occur in parallel. These
include the induction of ‘protective’ allergen-specific
IgG1, IgG4 and IgA2 antibodies. There is an early
paradoxic increase in specific IgE antibodies accom-
panied by distinct blunting of seasonal pollen-induced
increases in specific IgE. There follows a delayed-in-
time gradual reduction in allergen-specific IgE to the
sensitising allergen over several years during and af-
ter withdrawal of immunotherapy.
AIT MODULATE DENDRITIC CELLS TO INDUCE
REGULATORY T CELLS
In vivo murine and in vitro human studies have
shown that pro-inflammatory epithelial derived me-
diators and cytokines such as TSLP, IL-25, IL-33
prime DCs to polarize naïve T cell responses towards
a pro-allergic Th2 phenotype.31-35 AIT may dampen
these inflammatory epithelial responses resulting in
induction of tolerogenic DCs which are able polarize
T cells towards an IL-10 producing Treg phenotype.
The inducible IL-10+ Tregs may in turn suppress pro-
inflammatory DCs and modulate Th2 responses.35-37
AIT has been shown to augment peripheral DC
TLR9-mediated innate immune function.38 A 3-5-fold
increase in IFN-α production by plasmacytoid den-
dritic cells (pDCs) in response to CpG stimulation in
vitro was demonstrated in subjects who received
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Fig.　1　Time course of response to subcutaneous immunotherapy. Suppression of the 
late allergic response (LPR) at weeks 2-4 is associated with an increase in IL-10 produc-
tion. Inhibition of the early allergic responses (EPR) is observed at weeks 8-16 and paral-
lels the induction of immunereactive IgG4 antibodies and serum IgG-associated ‘blocking 
antibodies’. Shaded grey area represents the up-dosing phase of subcutaneous immuno-
therapy (cluster regimen). The green line indicates the seasonal increase in grass pollen 
counts. Reproduced with permission modifi ed from Clin Exp Allergy 2008; 38: 1074-88 
(ref. 28). For original supporting data, see ref. 15.
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HDM specific AIT. A recent study revealed that dif-
ferent subsets of human DCs enriched from periph-
eral blood could preferentially induce IL-10+ regula-
tory T cells and subsequently suppressed in vitro
allergen-driven Th2 responses.30
A novel inhibitory cytokine namely IL-27, which is
produced by dendritic cells following TLR4 stimula-
tion by LPS in vitro, has been shown to suppress T
helper 2 responses in patients with seasonal allergic
rhinitis.39 Interleukin (IL)-27 is a heterodimeric cy-
tokine that belongs to the IL-12 family and consists of
Epstein Bar inducible gene 3 (EBI-3)40 and IL-12p2841
(ref) (Fig. 2). IL-27 was shown to suppress grass pol-
len allergen-stimulated PBMC proliferation in a dose-
dependent manner, whereas mRNA expression for T-
bet and c-Maf was upregulated and GATA-3 was
downregulated. IL-27 significantly down-regulated
IL-4, IL-5 and up-regulated IL-10 and IFN-g mRNA ex-
pression. IL-27 inhibited IL-4 protein production from
Th2 clones when stimulated with anti-CD3CD28.
Moreover, T effector cell proliferation was sup-
pressed when grass pollen-stimulated IL-27-primed
DCs were cultured with T effector cells. Although
these findings identify inhibitory effects of IL-27 on
Th2 helper responses, its immunomodulatory role
during AIT remains to be determined. In another
study, proteomic analysis and mass spectroscopy of
peripheral human DCs identified 2 potential candi-
date proteins, namely stabilin 1 (STAB1) and the
complement component C1Q as potentially repre-
senting a tolerogenic signature of DCs. These pro-
teins may be relevant for inducing tolerogenic T
regulatory responses. For example ex vivo studies in-
volving quantitative polymerase chain reaction of pe-
ripheral blood mononuclear cells purified from blood
drawn beforeafter grass pollen SLIT revealed eleva-
tions in STAB1 and C1Q RNA expression that corre-
lated with the clinical response to immunotherapy.30
INDUCTION OF T REGULATORY CELLS BY AIT
Studies have highlighted the role of allergen-specific
Tregs in tolerance induction during AIT. The regula-
tory properties of IL-10+ (Tr1) and TGF-β+ inducible
Tregs and FoxP3+ natural Tregs (nTregs) have sev-
eral features in common. IL-10 and TGF-β produced
by CD4+CD25+ cells have been reported to modulate
Matsuoka T et al.
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Fig.　2　Mechanisms of immunological and clinical Tolerance in AIT. Low-dose and repeated allergen exposure 
at mucosal surfaces in atopic individuals drives IgE-facilitated antigen presentation and Th2-driven allergic in-
fl ammation. High-dose allergen administered by sublingual or subcutaneous immunotherapy results in immune 
deviation from a Th2 to a Th1-driven response. This is accompanied by an increase in the ratio of Th1 cytokines 
(IFN-γ, IL-12) to Th2 cytokines (IL-4, IL-5, and IL-13). There is also an induction of T regulatory cells [inducible 
Treg cells (iTreg) and natural Treg cells (nTreg)] and an increase in the regulatory cytokines IL-10, TGF-β and IL-
27 following immunotherapy that play an important role in suppressing Th2 responses and contribute towards the 
induction of allergen-specifi c IgA2 and in particular IgG4 antibodies with inhibitory activity. IgG4 antibodies are 
able to compete with IgE for allergen and thereby suppress mast cell and basophil activation and inhibit IgE-facil-
itated presentation of allergen-IgE complexes to dendritic cells and/or B cells.
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allergen-driven Th2 responses during and after
AIT.42-44 Tr1 cells inhibit allergen-driven proliferative
T cell responses and Th2 cytokine release.45 Whether
this suppression is IL-10-dependent is controver-
sial.43,45 Natural Tregs were first described by
Sakaguchi.46,48,49 They are identified by increased
expression of the intracellular transcription factor
FOXP3 together with a high expression of the cell
surface receptor IL-2 receptor (CD25) and low ex-
pression of IL-7 receptor (CD127).
In a randomized controlled study of SLIT with a
combination of house dust mite and grass pollen ex-
tracts, the epigenetic modification of Treg cells was
assessed. Methylated CpG sites within the Foxp3 lo-
cus of enriched memory CD45RO+Treg cells were
enumerated before and 12 months following immuno-
therapy. DNA methylation was decreased in CD45RO
+Treg cells at the FOXP3 locus in subjects after 12
months treatment with dual AIT whereas no changes
in FOXP3 locus DNA methylation were observed in
CD45RO+ Treg cells in either placebo-treated allergic
participants nor healthy normal controls.47 These
findings support the notion that FoxP3 Tregs are in-
duced following AIT and that this property of T regu-
latory cells is confined to the memory T cell compart-
ment.
The inhibitory characteristics nTregs in vitro and
in vivo have been described in numerous studies.48,49
In addition to the release of soluble inhibitory media-
tors and cytokines regulation by nTregs is thought to
Allergen Immunotherapy and Tolerance
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Fig.　3　Effects of 2 years grass pollen subcutaneous immunotherapy on seasonal changes 
in the nasal mucosa during the pollen season. By in situ hybridisation there were signifi cant 
increases in cells expressing mRNA for the regulatory cytokines IL-10 and TGF-β during the 
pollen season after immunotherapy when compared to placebo-treated patients - panels a) 
and b). These changes paralleled signifi cant inhibition of seasonal increases in mast cells (c-
kit+ cells) and eosinophils (EG2+ cells) by immunostaining - c) and d). Examples of in situ 
hybridisation (for TGF-β) and immunostaining (for EG2+ cells) are shown - e) and f). (Data 
obtained from references 55-58).
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depend, at least in part, on mechanisms involving di-
rect cell-cell contact.48,49 Functional roles have been
proposed for membrane CTLA-4,49 surface-bound
TGF-β49 and the glucocorticoid-induced TNF recep-
tor (GITR).45 nTregs modulate allergen-specific T cell
responses in healthy, non-atopic individuals. In-
creased functional regulatory T cell activity and as
mentioned above, elevated levels of IL-10 from
allergen-stimulated peripheral blood mononuclear
cells (PBMC) cultures have been demonstrated
within 2-4 weeks of commencing immunotherapy.15
Allergen specific Tr1 cells have also been reported
following birch pollen AIT.42 In the same study, en-
riched peripheral Tr1 cells inhibited allergen-driven
proliferative responses. This suppression was inhib-
ited by neutralising IL-10.42
T regulatory cells may produce TGF-β, a cytokine
with potent immunomodulatory properties. Thus
TGF-β inhibits differentiation of Th1 and Th2 cells by
down regulating the expression of T-bet and GATA-
3.50,51 TGF-β induces the expression of FoxP3 and
stimulates the development of nTregs.52 It promotes
the expression of CTLA-4 on Treg cells.53,54 In addi-
tion TGF-β favours B cells to class switch and pro-
duce IgA antibodies a recently described feature of al-
lergen immunotherapy.55 Furthermore, downregula-
tion of IgE and FcεRI expression on Langerhans cells
(LCs) has been reported. These findings support a
role for TGF-β in maintaining and inducing peripheral
tolerance during AIT.
Successful subcutaneous pollen immunotherapy
has been associated with increased numbers of Tr1
and nTregs in the nasal mucosa.55-57 These increases
in Treg cells within the nasal mucosa were associated
with reduced numbers of local c-kit-positive mast
cells58 and eosinophils59 (Fig. 3) and with clinical im-
provement.59 Increased numbers of granzyme B+ and
IL-10+ CD8+ Foxp3+ Treg cells were also shown in
Matsuoka T et al.
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healthy control subjects and from house dust mite-
sensitive asthmatics before and 6 and 12 months after
treatment. Pam3CSK4 (a synthetic TLR2 ligand) and
Der p 2 co-stimulation expanded the CD8+CD25+
Foxp3+ Treg population and inhibited HDM-induced
IL-4 production in PBMCs.60 IL-10 production by T
cells has been consistently shown in several stud-
ies.15,41,61 IL-10 and IL-4 synergistically acts on B cells
to favour B cell class switch towards IgG4 antibody.62
In addition, IL-10 has numerous anti-inflammatory
characteristics that include inhibition of mast cell acti-
vation by IgE,63 inhibition of the production of Th2
cytokines, including IL-5,44 and induction of T cell hy-
poresponsiveness through IL-10 receptor-dependent
blockade of CD28 phosphorylation.64 The latter is an
essential co-stimulatory pathway for T cells during
allergen-induced activation by APCs. Alternative
mechanisms of tolerance during allergen-specific im-
munotherapy might include selective apoptosisdele-
tion of antigen-specific Th2 cell responses 65 andor a
failure of co-stimulation leading to T cell anergy.66
IL-10+ B CELLS (B REGULATORY CELLS)
Several studies have reported that murine B cells can
produce IL-10.67,68 These cells are phenotypically
characterized as CD1dhiCD5+CD19hi and are called
B10 cells.67 B10 cells have been shown to suppress T
cell-dependent inflammatory responses.67,68 Adoptive
transfer of CD1dhiCD5+ B cells from oxazolone-
sensitized mice inhibited contact sensitivity reactions
to oxazolone in recipient mice in a IL-10-dependent
and antigen-specific manner.67 In another study, B
cells induced by Schistosoma mansoni protected
against anaphylaxis and allergic airway inflammation
in an IL-10-dependent manner. IL-10+ Bregs sup-
pressed Th2 cells and induced Treg cells, which fur-
ther inhibited the Th2 allergic inflammatory re-
sponses.69 In humans, B10 cells have been identified
within the CD24hiCD27+ or CD19CD24hiCD38hi B
cell compartment.70 Moreover, higher proportion of
IL-10-producing CD5+ peripheral blood B cells were
observed in healthy controls in response to the milk
antigen casein when compared with subjects with
cow’s milk allergy.71 These findings suggest that
Breg cells may be involved in the maintenance of tol-
erance to allergens. In a recent study,72 human IL-10
producing B regulatory cells were identified and
shown to express the phenotypic markers CD25 and
CD71 together with low expression of CD73. In stud-
ies of peripheral blood from patients with bee venom
allergy enriched CD73lowCD25hiCD71hi B cells pro-
duced high concentrations of IL-10 and inhibited bee
venom phospholipase-A (PLA)-specific CD4 T-cell
proliferation.72 PLA-specific B cells isolated from non-
allergic beekeepers showed increased expression of
IL-10 and IgG4. Moreover, in a limited number of
subjects, the proportion of IL-10 producing PLA-
specific B cells was increased following bee venom-
specific immunotherapy.72 It is likely that the ob-
served anti-inflammatory IgG4 responses observed
following AIT is mediated by IL-10 produced from a
variety of cells, including T cells, B cells and also ac-
cessory cells such as monocytes andor dendritic
cells.
IMMUNE DEVIATION FROM Th2 TO Th1 RE-
SPONSES
A shift in the ratio of Th1 and Th2 cytokines has been
reported in target organs.73,74 Horiguchi and col-
leagues demonstrated an increase in allergen specific
Th2 clones after the Japanese cedar pollen season.
SLIT using Japanese cedar pollen extract was associ-
ated with a decrease in the frequency of Th2 clones
induced by pollen exposure.26 Several studies have
reported that the induction of long-term clinical toler-
ance during AIT is associated with a delayed immune
deviation of allergen-specific Th2 to Th1 responses.75
However, not all in vitro studies of peripheral blood T
cells from subjects following AIT have demonstrated
reductions in allergen-driven proliferative and Th2 cy-
tokine responses.76 Several reasons may account for
these discrepancies such as variations in laboratory
methodology and lack of standardization of allergen
extracts used for immunotherapy.
AIT has been shown to modify the cytokine profile
of T cells recruited into the target organ.76 Nasal mu-
cosal biopsies from AIT treated patients, performed
during the allergen-induced late allergic response to
grass pollen, revealed increases in IFN-γ mRNA ex-
pressing cells74 and both increases in IFN-γ and de-
creases in IL-4 protein levels in nasal fluid.77 Interest-
ingly, increases in the numbers of IFN-γ mRNA+ cells
in the nasal mucosa that accompanied suppression of
the late response after allergen challenge outside the
pollen season inversely correlated with clinical symp-
toms during the pollen season.74 In AIT treated pa-
tients, there was also a clear association between the
suppression of the late cutaneous allergic responses
and enhanced IL-12 mRNA expression in the skin.
The latter correlated directly with increased IFN-γ
and inversely with IL-4 expression.78 The principle
cell source of IL-12 was found to be macrophages,
whereas at the time, specific probes for dendritic cell
subsets were unavailable for probing the dendritic
cell as an alternative source of IL-12. Similar studies
demonstrated that AIT inhibited seasonal increases
in IL-5 and IL-9 mRNA expressing cells in the nasal
mucosa.58,59 Eosinophil numbers in the nasal mucosa
after grass pollen immunotherapy correlated directly
with IL-5 expression and inversely with clinical symp-
toms during the pollen season i.e suppression of
eosinophils correlated with clinical improvement.59
These studies accentuate the relevance of studying
“target organ” immune responses rather than the pe-
ripheral blood, particularly for diseases induced by in-
halant allergens.
Allergen Immunotherapy and Tolerance
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Fig.　4　Persistence of allergen-specifi c IgG associated inhibitory antibodies after discontinuation of AIT. (a) 
Steady increase in P. pratense-specifi c IgG antibodies in the AIT-treated group (who received 6-7 yr AIT) 
and a marked decrease in the AIT withdrawn group (who received 3-4 yr AIT followed by placebo injections 
for 3 years). (b) In contrast there is persistence of serum inhibitory activity for IgE-faciliatetd allergen bind-
ing (FAB) following withdrawal of AIT despite an 80% reduction in Specifi c IgG levels (adapted with permis-
sion from James LK et al. J Allergy Clin Immunol 2011; 127: 509-516.
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IgG4 AND TOLERANCE INDUCTION DURING
AND AFTER AIT
Increases in serum IgG and IgG4 antibodies to the
sensitizing allergen during successful AIT has been
well reported in several studies.79-86 These antibodies
have been shown to have inhibitory properties and
were first described by Cooke and colleagues in
1935.86 Later, Lichtenstein and colleagues described
these inhibitory antibodies to be confined to the IgG
fraction in serum.87 IgA antibodies have also shown
to have inhibitory properties.88 These inhibitory anti-
bodies or ‘blocking antibodies’ are thought to com-
pete with IgE for allergen binding to CD23 on the
surface of B cells.89,90 This suppression of allergen-
IgE-binding to B cells (IgE-facilitated binding, IgE-
FAB) correlated closely with the observed subse-
quent inhibition of allergen-induced T-cell prolifera-
tion29,91,92 (following IgE-facilitated allergen presenta-
tion to T cells IgE-FAP). This inhibitory activity for
IgE-facilitated allergen binding to B cells that was
present in post-immunotherapy serum was shown
by affinity chromatography to co-purify largely with
IgG4.56,92 Measurement of IgE-facilitated allergen-IgE
complexes to B cells (IgE-FAB) and its inhibition by
post-immunotherapy IgG-containing sera was vali-
dated according to Helsinki guidelines as a functional
assay for testing IgG inhibitory activity in sera in
large-scale immunotherapy trials.91 By use of this as-
say, increases in serum inhibitory activity for IgE-
FAB was shown to be immunotherapy dose-
dependent and time-dependent, peaking at 3-6
months after commencement of immunotherapy and
correlated more closely with suppression of seasonal
symptoms when compared with measurement of im-
munoreactive levels of allergen-specific IgG4.79
More recently, Scadding and colleagues have
shown that grass pollen sublingual immunotherapy
is also associated with increases in antigen-specific
IgG1 and IgG4.82 In parallel experiments in the same
participants there was a time-dependent increase in
serum inhibitory activity for IgE-FAB.82 Horiguchi
and colleague have demonstrated increases in
allergen-specific IgG4 after sublingual immunother-
apy for Japanese cedar pollen allergy.26
Long-term clinical tolerance after discontinuation
of subcutaneous immunotherapy is a cardinal feature
of immunotherapy that distinguishes it from treat-
ment with anti-allergic drugs.11 Long-term tolerance
after subcutaneous immunotherapy is accompanied
by persistent elevations in serum IgG-associated in-
hibitory activity for IgE-FAB that persists for at least
3 years after discontinuation of treatment (Fig. 4).11,81
In this study, IgG-associated inhibitory activity, rather
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than absolute levels of IgG4 antibodies, correlated
with clinical efficacy following withdrawal of treat-
ment. In patients with a history of insect venom ana-
phylaxis who underwent subcutaneous bee venom
immunotherapy, increases in serum allergen-specific
IgG and associated inhibitory activity for IgE-FAB
during treatment were not maintained following dis-
continuation of immunotherapy, implying that differ-
ent mechanisms may underlie the long-term toler-
ance observed after discontinuation of venom immu-
notherapy.90,93
Recent data has confirmed that grass pollen sublin-
gual tablet immunotherapy is also associated with
long-term clinical remission.94 In a double blind trial
of 3 years treatment with grass allergen tablets fol-
lowed by 2 years follow up, participants who had re-
ceived active treatment showed sustained and persis-
tent clinical improvement for 2 years after withdrawal
of treatment that was accompanied by persistent in-
creases in serum IgG4 and associated inhibitory ac-
tivity for IgE-FAB whereas this was not observed in
placebo-treated subjects.94 Taken together these
studies support that measurement of serum inhibi-
tory activity for IgE-FAB has potential as a surrogate
marker of clinical efficacy and tolerance, whereas it
remains to be tested whether IgE-FAB inhibition is
able to predict responsiveness to immunotherapy in
individual subjects.
CONCLUSION
Allergen immunotherapy is effective and induces
long-lasting immunological and clinical tolerance that
persists for years following cessation of treatment.
Immunotherapy is associated with suppression of al-
lergic inflammation in target organs and increases in
IgG4 and IgA2-associated blocking antibodies. The
induction of blocking antibodies is accompanied by
suppression of undesired allergen-specific Th2 cell
responses. This suppression occurs within weeks or
months as a result of the induction of regulatory T
cells that exert their effects by mechanisms involving
cell-cell contact, and also by release of immunomodu-
latory cytokines such as IL-10 and TGF-β. The more
delayed-in-time appearance of antigen-specific Th1 re-
sponses and alternative mechanisms such as Th2-cell
anergy andor apoptosis may also be involved. A
greater understanding of mechanisms has provided
potential surrogate clinicalimmunological biomark-
ers of efficacy and has led to novel immunotherapy
strategies, whereas the mechanisms of long-term
clinical tolerance remains yet to be further fully eluci-
dated.
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